Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia

The commercial availability of anamorelin, Japan's first therapeutic agent for cancer cachexia in 2021, led to an investigation into its prescription patterns at Toyama University Hospital. We aimed to analyze anamorelin prescription trends and outcomes among cancer cachexia patients. A retrosp...

Full description

Saved in:
Bibliographic Details
Published inJournal of palliative medicine
Main Authors Tambo, Yoshihiro, Kajiura, Shinya, Yoshida, Akihiro, Chikaoka, Shingo, Tanabe, Yuki, Kanai, Nahoko, Takayuki, Ando, Ueda, Akira, Moto, Iori, Nakayama, Yurika, Shima, Tomoko, Matsushita, Yukiko, Mizukami, Tatsuji, Kainuma, Mosaburou, Yasuda, Ichiro, Hayashi, Ryuji
Format Journal Article
LanguageEnglish
Published United States 01.07.2024
Subjects
pancreatic cancer
meal intake
retrospective study
Online AccessGet more information

Cover

Abstract The commercial availability of anamorelin, Japan's first therapeutic agent for cancer cachexia in 2021, led to an investigation into its prescription patterns at Toyama University Hospital. We aimed to analyze anamorelin prescription trends and outcomes among cancer cachexia patients. A retrospective study from July 2021 to December 2022 examined 88 cases, assessing demographics, cancer types, prescription locations, and meal intake changes. Anamorelin usage was predominant during chemotherapy, especially for pancreatic cancer in outpatient settings. Approximately 30% experienced increased meal intake. Chemotherapy-initiated cases had a longer median duration (55 days) compared with best supportive care only cases (12 days). Anamorelin demonstrated significant prescription patterns, particularly during chemotherapy for pancreatic cancer in outpatient settings, suggesting potential efficacy enhancements when administered with chemotherapy in cancer cachexia management. The study underscores the importance of tailored approaches to optimize anamorelin's therapeutic benefits.
AbstractList The commercial availability of anamorelin, Japan's first therapeutic agent for cancer cachexia in 2021, led to an investigation into its prescription patterns at Toyama University Hospital. We aimed to analyze anamorelin prescription trends and outcomes among cancer cachexia patients. A retrospective study from July 2021 to December 2022 examined 88 cases, assessing demographics, cancer types, prescription locations, and meal intake changes. Anamorelin usage was predominant during chemotherapy, especially for pancreatic cancer in outpatient settings. Approximately 30% experienced increased meal intake. Chemotherapy-initiated cases had a longer median duration (55 days) compared with best supportive care only cases (12 days). Anamorelin demonstrated significant prescription patterns, particularly during chemotherapy for pancreatic cancer in outpatient settings, suggesting potential efficacy enhancements when administered with chemotherapy in cancer cachexia management. The study underscores the importance of tailored approaches to optimize anamorelin's therapeutic benefits.
Author Nakayama, Yurika
Ueda, Akira
Yoshida, Akihiro
Tanabe, Yuki
Kanai, Nahoko
Chikaoka, Shingo
Yasuda, Ichiro
Hayashi, Ryuji
Moto, Iori
Mizukami, Tatsuji
Shima, Tomoko
Kajiura, Shinya
Matsushita, Yukiko
Kainuma, Mosaburou
Takayuki, Ando
Tambo, Yoshihiro
Author_xml – sequence: 1
  givenname: Yoshihiro
  surname: Tambo
  fullname: Tambo, Yoshihiro
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
– sequence: 2
  givenname: Shinya
  surname: Kajiura
  fullname: Kajiura, Shinya
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
– sequence: 3
  givenname: Akihiro
  surname: Yoshida
  fullname: Yoshida, Akihiro
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
– sequence: 4
  givenname: Shingo
  surname: Chikaoka
  fullname: Chikaoka, Shingo
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
– sequence: 5
  givenname: Yuki
  surname: Tanabe
  fullname: Tanabe, Yuki
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
– sequence: 6
  givenname: Nahoko
  surname: Kanai
  fullname: Kanai, Nahoko
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
– sequence: 7
  givenname: Ando
  surname: Takayuki
  fullname: Takayuki, Ando
  organization: The Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan
– sequence: 8
  givenname: Akira
  surname: Ueda
  fullname: Ueda, Akira
  organization: The Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan
– sequence: 9
  givenname: Iori
  surname: Moto
  fullname: Moto, Iori
  organization: The Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan
– sequence: 10
  givenname: Yurika
  surname: Nakayama
  fullname: Nakayama, Yurika
  organization: The Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan
– sequence: 11
  givenname: Tomoko
  surname: Shima
  fullname: Shima, Tomoko
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
– sequence: 12
  givenname: Yukiko
  surname: Matsushita
  fullname: Matsushita, Yukiko
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
– sequence: 13
  givenname: Tatsuji
  surname: Mizukami
  fullname: Mizukami, Tatsuji
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
– sequence: 14
  givenname: Mosaburou
  surname: Kainuma
  fullname: Kainuma, Mosaburou
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
– sequence: 15
  givenname: Ichiro
  surname: Yasuda
  fullname: Yasuda, Ichiro
  organization: The Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan
– sequence: 16
  givenname: Ryuji
  surname: Hayashi
  fullname: Hayashi, Ryuji
  organization: Palliative Care Team, Toyama University Hospital, Toyama, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38949886$$D View this record in MEDLINE/PubMed
BookMark eNo1j81KxDAYRYMozo8u3UpeoPVL0jQJrkrxDwecxbge0vSrk2GaljQD-vaOqKuzuRzuWZDzMAQk5IZBzkCbu_3Y5xx4kQNIOCNzJqXKlCpgRhbTtAc4jUBekpnQpjBal3Pyuo44uejH5IdA1zYljIEOHa2C7YeIBx_uqaWbHUY74jF5R6sPDIl2Q6S1DQ5_4Hb46e0VuejsYcLrPy7J--PDpn7OVm9PL3W1yhznImUtkyBOP8Cw0kjdlE3TGA6S8U5ICWha1IojlK4FVzijFGPoDAqhJUcn-ZLc_nrHY9Njux2j72382v5X8W9RO02G
ContentType Journal Article
DBID NPM
DOI 10.1089/jpm.2024.0050
DatabaseName PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Economics
EISSN 1557-7740
ExternalDocumentID 38949886
Genre Journal Article
GroupedDBID ---
0R~
34G
36B
39C
4.4
53G
5GY
AAWTL
ABBKN
ABIVO
ABJNI
ACGFS
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
BNQNF
CS3
DU5
EBS
F5P
IM4
MV1
NPM
NQHIM
O9-
P2P
RML
UE5
ID FETCH-LOGICAL-c223t-d15039050916958b6bbb920512f3550e9de872e06cd0c4c97711ec9e33852ec52
IngestDate Sat Nov 02 12:29:28 EDT 2024
IsPeerReviewed true
IsScholarly true
Keywords pancreatic cancer
meal intake
retrospective study
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c223t-d15039050916958b6bbb920512f3550e9de872e06cd0c4c97711ec9e33852ec52
PMID 38949886
ParticipantIDs pubmed_primary_38949886
PublicationCentury 2000
PublicationDate 2024-Jul-01
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-Jul-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of palliative medicine
PublicationTitleAlternate J Palliat Med
PublicationYear 2024
SSID ssj0008905
Score 2.439738
Snippet The commercial availability of anamorelin, Japan's first therapeutic agent for cancer cachexia in 2021, led to an investigation into its prescription patterns...
SourceID pubmed
SourceType Index Database
Title Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia
URI https://www.ncbi.nlm.nih.gov/pubmed/38949886
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFA5eYPoi3u-SB99GtUubtsGnORRRFMEN9EmSNN26sXboBPXXe5JedvGC-tKGptlKvtPTr6fnfEHokDos4mFQs5j0PcslrrS4Dy8rCpqO8DiRSn_Rvb7xLlru5T29H5UrmuqSoTiS71_WlfwHVTgGuOoq2T8gW_4oHIA24AtbQBi2v8JY50-Ud_2tUco07K-ecJ0_q9did06rXKdVFEVW1XrbyDGlT9WGBlzvALfXmH9DUwdcB2RMgtH0d_gm7wsTaX1InztxJ35KS_fNu_GLWcGoeteJkzc-ci5wZpjFcnsTQxqduMfTXjmmnY4HJIhbJq_C8yR3otQH1p7JMH1y0XagFU67Ay0DQLR0OZ04D2Z40Dd4AZVyWZAJZf_cO6WYXXTNolk_0L7vRkdw8qdzwGyaa61C-3jiOhZRpRg79ZZh2EZzGS3l84_rGeYraEYlq2ihqCJ_XkWV6xyMNXQ1bgY4NwOcRnhkBieY4zEjwMYIMBgBzowAF0awjlrnZ83GhZWvkWFJIHZDKwRC7zAt4lPzGA2EJ4RgBDwtiYBJ2oqFKvCJsj0Z2tKVwPZrNSWZcpyAEiUp2UBzSZqoLYSBigrqCuYxP9L11Vz6jhMRpkQI_xHJbbSZTcnjIBNCeSwma-fbnl20ODKRPTQfwZ2n9oHGDcWBweUD9hpHHA
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prescription+Pattern+of+Anamorelin%3B+a+Therapeutic+Agent+for+Cancer+Cachexia&rft.jtitle=Journal+of+palliative+medicine&rft.au=Tambo%2C+Yoshihiro&rft.au=Kajiura%2C+Shinya&rft.au=Yoshida%2C+Akihiro&rft.au=Chikaoka%2C+Shingo&rft.date=2024-07-01&rft.eissn=1557-7740&rft_id=info:doi/10.1089%2Fjpm.2024.0050&rft_id=info%3Apmid%2F38949886&rft_id=info%3Apmid%2F38949886&rft.externalDocID=38949886